News
hereditary angioedema, DAWNZERA
Digest more
Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...
Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...
Stocktwits on MSN1d
Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy
Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for ...
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback